Affymetrix (Santa Clara, California) And Tessarae Collaborate To Help Researchers Better Respond To Biodefense and Pandemic Infectious Disease Threats

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that it has granted Tessarae Inc. non-exclusive access to its microarray technology to develop and market epidemiological research tests for public health and biodefense surveillance. As part of the Powered by Affymetrix™ program, the TessArray™ kits simultaneously detect and identify hundreds of strains of natural and emergent viral and bacterial pathogens, as well as biothreat agents. The resulting information will enable researchers to better understand and respond to pandemic infectious disease threats.

Back to news